Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Surgery and Cancer. Her work carried out in the field of Breast cancer brings together such families of science as Stage and Prospective cohort study. Her studies in Oncology integrate themes in fields like Trastuzumab, Survival rate, Young adult, Metastasis and Mastectomy.
Elizabeth A. Mittendorf has included themes like Vitamin D and neurology, Acosog z0011 and Risk factor in her Surgery study. The concepts of her Cancer study are interwoven with issues in Immunology and Bioinformatics. Her Sentinel lymph node study incorporates themes from Carcinoma, Dissection and Axilla.
Elizabeth A. Mittendorf focuses on Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Elizabeth A. Mittendorf combines subjects such as Stage, Surgery, Clinical trial and Immunology with her study of Breast cancer. Her work on Prospective cohort study as part of general Surgery research is frequently linked to In patient, thereby connecting diverse disciplines of science.
Her work in Oncology addresses issues such as Mastectomy, which are connected to fields such as Radiation therapy and Retrospective cohort study. Her Cancer research includes themes of Gastroenterology and Proportional hazards model. Her work deals with themes such as Biopsy, Dissection, Lymph and Axilla, which intersect with Sentinel lymph node.
Elizabeth A. Mittendorf mainly investigates Breast cancer, Internal medicine, Oncology, Triple-negative breast cancer and Cancer. The various areas that she examines in her Breast cancer study include Cancer research, Surgical oncology and Immunotherapy. Her research in Cancer research tackles topics such as Immune system which are related to areas like Monoclonal antibody.
Her study in Oncology is interdisciplinary in nature, drawing from both Pembrolizumab, Clinical trial, Phases of clinical research, Metastatic breast cancer and Randomized controlled trial. In her study, which falls under the umbrella issue of Triple-negative breast cancer, Cyclophosphamide and Stromal tumor is strongly linked to Neoadjuvant therapy. Her work on Axillary Lymph Node Dissection and Sentinel lymph node as part of general Cancer research is frequently linked to Context, bridging the gap between disciplines.
Her main research concerns Breast cancer, Internal medicine, Oncology, Chemotherapy and Triple-negative breast cancer. Her Breast cancer research is under the purview of Cancer. Her studies deal with areas such as Regimen and PTEN as well as Cancer.
Her Oncology research incorporates themes from Clinical trial, Metastatic breast cancer, Randomized controlled trial and Disease, Nodal disease. Her work investigates the relationship between Chemotherapy and topics such as Neoadjuvant therapy that intersect with problems in Germline. Her Triple-negative breast cancer study combines topics from a wide range of disciplines, such as Cancer research, Atezolizumab, Immune system and Median follow-up.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Sonia A. Melo;Linda B. Luecke;Christoph Kahlert;Agustin F. Fernandez.
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt.
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao.
Cancer immunology research (2014)
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Armando E. Giuliano;James L. Connolly;Stephen B. Edge;Elizabeth A. Mittendorf.
CA: A Cancer Journal for Clinicians (2017)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle;Wei T. Yang;Savitri Krishnamurthy;Elizabeth A. Mittendorf.
Journal of Clinical Oncology (2016)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji.
The Lancet (2020)
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
Naoki Niikura;Jun Liu;Naoki Hayashi;Elizabeth Ann Mittendorf.
Journal of Clinical Oncology (2012)
Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Judy C. Boughey;Karla V. Ballman;Huong T. Le-Petross;Linda M. McCall.
Annals of Surgery (2016)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Jong-Ho Cha;Wen-Hao Yang;Weiya Xia;Yongkun Wei.
Molecular Cell (2018)
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
Kelly K. Hunt;Min Yi;Elizabeth A. Mittendorf;Cynthia Guerrero.
Annals of Surgery (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: